Penn Pharma’s Large-Scale Commercial Manufacturing Suite Now Operational
Penn Pharma has revealed plans to invest a further £3 million to increase large-scale commercial manufacturing capabilities at its site in South Wales. Penn has declared that this new suite is operational less than 12 months after first announcing the plans.
This is in addition to the £14 million previously invested by Penn expanding its site with a purpose-built contained manufacturing facility, which opened in September 2013.
The new manufacturing suite includes granulation, tabletting and coating capability. This investment allows Penn Pharma to increase capacity for both current and future clients and improve its ability to service the growing market need for large-scale commercial outsourcing solutions.
Penn Pharma Chief Operating Officer, Mark Dean-Netscher commented: “We continue to grow and invest in new technology and our people. The decision to invest in additional capacity ensures we are able to offer our clients leading-edge technology across all manufacturing areas, continuously improve our service offering and exceed our clients’ expectations by offering the best possible service.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.